Aldosterone responses to angiotensin II were evaluated in normal subjects in 3 conditions, (1) with suppression of neither ACTH secretion nor angiotensin II, (2) with suppression of ACTH by dexamethasone, and (3) with suppression of both ACTH and angiotensin II by combined administration of dexamethasone and captopril. Baseline levels of plasma aldosterone were significantly lowered by administration of either dexamethasone or both dexamethasone and captopril. Aldosterone responsiveness to angiotensin-II was not altered by suppression of ACTH secretion. However, the responsiveness was significantly enhanced during suppression of both ACTH and angiotensin II. These results suggest that aldosterone response to angiotensin II in normal man is not dependent upon endogenous ACTH secretion, but to an action of angiotensin II on the pituitary gland to release ACTH. The combined administration of dexamethasone and captopril may be a useful maneuver to assess more precisely the reactivity of the adrenal cortex to angiotensin II in man.
I
T is widely recognized that the renin-angiotensin system is one of the major regulators of aldosterone production in man. further react with the infused octapeptide, since unoccupied adrenal receptor sites for angiotensin II may increase when endogenous angiotensin II levels decline after treatment. It is also possible that captopril can directly sensitize the adrenal cortex to angiotensin II. In any case, the simultaneous administration of dexamethasone and captopril may be a useful maneuver to assess in more detail the responses of the adrenal cortex to angiotensin II, since the protocol excludes endogenous factors (angiotensin II and/or ACTH) which affect the sensitivity. Therefore, the combined administration of dexamethasone and captopril may offer an opportunity to examine the aldosterone response to exogenous angiotensin II in cases with abnormal pituitary-adrenocortical and/or renin-angiotensin systems.
Our data indicate no differences in blood pressure responses to angiotensin II infusion between the control, dexamethasone-treated, and dexamethasone plus captopril-treated groups. Although the reasons for this discrepancy between the blood pressure and aldosterone responses are unclear, the relatively small infusion doses may be a contributing factor.
Previous data from humans17) showed that serum potassium levels were raised by long-term treatment of captopril. Further, data from earlier studies indicate that aldosterone secretion can be stimulated by increased potassium concentration.18),19) A direct effect of serum potassium on aldosterone secretion has been shown in studies in which potassium salts were infused directly into the adrenal artery of sheep with their adrenals transplanted into the neck.18) However, serum potassium levels did not change in the present study. This may indicate that the duration of captopril administration was too short to significantly raise the serum potassium levels. Therefore, serum potassium does not contribute to the enhanced response of aldosterone with captopril treatment. From these perspectives it is suggested that the aldosterone response to angiotensin II is not dependent upon ACTH secretion, and that simultaneous administration of dexamethasone and captopril may be a useful approach to clarify the adrenal responses to exogenous angiotensin II in man.
